Skip to Main Content

Try STAT+ TODAY

Biosimilars

Most Read

Pharmalot Ed Silverman

STAT Plus: Medicare Part D and its beneficiaries could have saved millions if more biosimilars were accessible

Pharmalot Ed Silverman

STAT Plus: AbbVie settles litigation with another drug maker over a biosimilar version of Humira

First Opinion Dana P. Goldman and Tomas J. Philipson

Biosimilars competition helps patients more than generic competition

Health Ed Silverman

Virtual Event: The evolving landscape for biosimilars

Health Michelle Andrews — Kaiser Health News

Biosimilar drugs gain ground in U.S., but concerns linger about when patients can switch

First Opinion Gillian Woollett

The FDA just broke the logjam on interchangeable biologics. Here’s what that decision means

Pharmalot Ed Silverman

STAT Plus: FDA scolds Amgen over a misleading ad that could deter use of biosimilar versions of its drug

Opinions+ Pierre Bourdage

STAT Plus: Three steps toward creating a functioning U.S. biosimilars market

All Coverage

Opinions+ Thomas Newcomer

STAT Plus: Removing barriers to biosimilar adoption in the United States

Pharma Ed Silverman

Virtual Event: Biosimilars’ Meteoric Moment

advertisement

First Opinion Jeff Baldetti

STAT Plus: Market share isn’t the only metric for biosimilars’ success

Pharmalot Ed Silverman

STAT Plus: U.S. appeals court panel decides AbbVie’s ‘patent thickets’ for Humira don’t thwart competition

Pharmalot Ed Silverman

STAT Plus: FDA approves an interchangeable biosimilar version of Humira, but health care savings are dubious

Pharma Ed Silverman

STAT Plus: AbbVie loses a lawsuit over Humira trade secrets it claimed were stolen

First Opinion Howard S. Hochster

FDA’s naming rule for biosimilars has undermined Congress and health care

Pharmalot Ed Silverman

STAT Plus: FDA approves the first interchangeable biosimilar insulin. Will it really lower the cost?

Pharmalot Ed Silverman

STAT Plus: AbbVie accuses a company of recruiting an employee in order to steal Humira secrets

Pharmalot Ed Silverman

STAT Plus: Once again, the viability of the U.S. biosimilar market is thrown into question

Pharmalot Ed Silverman

STAT Plus: In a petition, Boehringer warns FDA its definition of ‘strength’ threatens biosimilar competition

Pharmalot Ed Silverman

STAT Plus: What doubts? New forecast says biosimilars will cut U.S. drug spending by $100 billion in five years

Pharmalot Ed Silverman

STAT Plus: Mylan launches a low-cost biosimilar insulin, but experts say many patients may not save on costs

Pharmalot Ed Silverman

STAT Plus: Tiny Denmark saved lots of money on biosimilar Humira, while Americans are still paying big bucks

Pharmalot Ed Silverman

STAT Plus: Biosimilars got the cold shoulder from health plans when it came to preferred coverage

Pharmalot Ed Silverman

STAT Plus: Large employers could have saved money if more biosimilars had been prescribed

First Opinion Carol Lynch

Biosimilars could disappear if the Supreme Court overturns the ACA

First Opinion Sean McGowan

Five years on, biosimilars need support from all health care players

First Opinion Leah Christl

From bench to bedside, biologics require excellence at every stage

Pharmalot Ed Silverman

STAT Plus: Insulin makers object to FDA proposal for speeding arrival of biosimilar insulins

Business Matthew Herper

Merck to spin off new $6.5 billion firm focused on women’s health, older drugs

Pharmalot Ed Silverman

STAT Plus: FDA and FTC vow to attack anti-competitive practices that limit biosimilar uptake

Politics Lev Facher

STAT Plus: Airing frustrations with pharma, a Republican FTC commissioner just endorsed Medicare negotiation

Pharmalot Ed Silverman

STAT Plus: Generic makers will appeal ruling that allows California to proceed with law banning pay-to-delay deals

Pharmalot Ed Silverman

STAT Plus: More hospital drug spending is going toward cancer immunotherapies